SCHEMBL15840557

SCHEMBL15840557

Cc1ccccc1NS(=O)(=O)c1ccc(NC(=S)Nc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
LMNA P02545 4/20 0.61
NPSR1 Q6W5P4 3/20 0.61
TP53 P04637 2/20 0.61
HTT P42858 2/20 0.61
POLB P06746 1/20 0.61
XBP1 P17861 1/20 0.61
ALOX12 P18054 1/20 0.61
FFAR1 O14842 1/20 0.56
CDK1 P06493 1/20 0.56
CCNB1 P14635 1/20 0.56
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56
CDK7 P50613 1/20 0.56
CCNH P51946 1/20 0.56
CCNA1 P78396 1/20 0.56
FFAR4 Q5NUL3 1/20 0.56
PPIA P62937 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840680 0.87 MAPT (0.68) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL15840630 0.81 MAPT (0.68) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL15840433 0.81 MAPT (0.64) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL15840562 0.80 GPR27 (0.60) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL15840816 0.78 PPIA (0.57) MAPTMEN1KMT2ALMNAHTT
SCHEMBL15840721 0.78 PPIA (0.58) MAPTMEN1KMT2ALMNAALOX12
SCHEMBL14403258 0.77 PTGES2 (0.65) MAPTMEN1KMT2ALMNAHTT
SCHEMBL22567938 0.76 MAPT (0.78) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL22024988 0.76 MAPT (0.62) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL12113068 0.75 MEN1 (0.78) MAPTMEN1KMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885MEN1 3121/4885KMT2A 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.